[
  {
    "ts": null,
    "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q1 2025 Update",
    "summary": "AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a quantitative, diversified approach. See more.",
    "url": "https://finnhub.io/api/news?id=51b45bd42e92498ec52abd010edf461044394127b04a8428f9c402a3b43b4ef8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750108183,
      "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q1 2025 Update",
      "id": 135312158,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a quantitative, diversified approach. See more.",
      "url": "https://finnhub.io/api/news?id=51b45bd42e92498ec52abd010edf461044394127b04a8428f9c402a3b43b4ef8"
    }
  },
  {
    "ts": null,
    "headline": "Merck - FDA Approves KEYTRUDA for PD-L1+ Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy",
    "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has approved KEYTRUDA , Merck's anti-PD-1 therapy, for the treatment of...",
    "url": "https://finnhub.io/api/news?id=de2e038126109494911ef053ad7af1539b2bc6f46cba545d719220de12a6037d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750065448,
      "headline": "Merck - FDA Approves KEYTRUDA for PD-L1+ Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy",
      "id": 135300802,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has approved KEYTRUDA , Merck's anti-PD-1 therapy, for the treatment of...",
      "url": "https://finnhub.io/api/news?id=de2e038126109494911ef053ad7af1539b2bc6f46cba545d719220de12a6037d"
    }
  },
  {
    "ts": null,
    "headline": "2 Wonderful Dividends Practically Giving Themselves Away",
    "summary": "Discover 2 undervalued stocks with strong fundamentals, wide moats, and solid dividends.",
    "url": "https://finnhub.io/api/news?id=59375a46904a4d4b13fcd2bc31185c9655e6fe6b1f80491ad3679fd5fbcf5955",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750062600,
      "headline": "2 Wonderful Dividends Practically Giving Themselves Away",
      "id": 135300336,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1462296278/image_1462296278.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover 2 undervalued stocks with strong fundamentals, wide moats, and solid dividends.",
      "url": "https://finnhub.io/api/news?id=59375a46904a4d4b13fcd2bc31185c9655e6fe6b1f80491ad3679fd5fbcf5955"
    }
  }
]